Mathieu Nonnenmacher, Harm van Bakel, Roger J Hajjar, Thomas Weber 

Slides:



Advertisements
Similar presentations
Molecular Therapy - Methods & Clinical Development
Advertisements

Volume 3, Issue 6, Pages (June 2001)
Volume 20, Issue 2, Pages (February 2012)
Human Gene Therapy: Adeno associated virus (aav)
Daniel Chi-Hong Lin, Alan D Grossman  Cell 
Molecular Therapy - Methods & Clinical Development
Volume 21, Issue 12, Pages (December 2013)
Volume 124, Issue 7, Pages (June 2003)
Volume 12, Issue 4, Pages (October 2012)
Volume 36, Issue 2, Pages (October 2009)
Volume 61, Issue 1, Pages S9-S15 (January 2002)
Volume 21, Issue 1, Pages (January 2013)
Molecular Therapy - Methods & Clinical Development
m6A Facilitates eIF4F-Independent mRNA Translation
Vaccinia virus as a subhelper for AAV replication and packaging
Interaction with PCNA Is Essential for Yeast DNA Polymerase η Function
Evidence that HIV-1 Encodes an siRNA and a Suppressor of RNA Silencing
Volume 22, Issue 3, Pages e5 (September 2017)
Volume 20, Issue 2, Pages (February 2012)
Direct Interactions of OCA-B and TFII-I Regulate Immunoglobulin Heavy-Chain Gene Transcription by Facilitating Enhancer-Promoter Communication  Xiaodi.
Volume 15, Issue 9, Pages (September 2007)
High-accuracy biodistribution analysis of adeno-associated virus variants by double barcode sequencing  Damien Marsic, Héctor R Méndez-Gómez, Sergei Zolotukhin 
Volume 16, Issue 5, Pages (March 2006)
Molecular Therapy - Nucleic Acids
Volume 22, Issue 11, Pages (November 2014)
Gang Wang, Na Zhao, Ben Berkhout, Atze T Das  Molecular Therapy 
Volume 8, Issue 1, Pages (July 2003)
Volume 26, Issue 4, Pages (April 2018)
Development of an HIV-Based cDNA expression cloning system
Volume 128, Issue 3, Pages (March 2005)
Volume 16, Issue 5, Pages (May 2008)
Volume 16, Issue 6, Pages (June 2008)
Brh2 Promotes a Template-Switching Reaction Enabling Recombinational Bypass of Lesions during DNA Synthesis  Nayef Mazloum, William K. Holloman  Molecular.
Volume 19, Issue 6, Pages (June 2011)
Andrei Kuzmichev, Thomas Jenuwein, Paul Tempst, Danny Reinberg 
Volume 15, Issue 2, Pages (February 2007)
Volume 19, Issue 4, Pages (April 2011)
Volume 25, Issue 2, Pages (February 2017)
Analyses of the Effects That Disease-Causing Missense Mutations Have on the Structure and Function of the Winged-Helix Protein FOXC1  Ramsey A. Saleem,
RNA Polymerase II Activity of Type 3 Pol III Promoters
Volume 15, Issue 11, Pages (November 2007)
SUMO-1 Modification Represses Sp3 Transcriptional Activation and Modulates Its Subnuclear Localization  Sarah Ross, Jennifer L Best, Leonard I Zon, Grace.
Volume 19, Issue 6, Pages (June 2011)
Molecular Therapy - Methods & Clinical Development
Efficient Sleeping Beauty DNA Transposition From DNA Minicircles
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
Effect of Genome Size on AAV Vector Packaging
Cheryl A. Carlson, Dmitry M. Shayakhmetov, André Lieber 
Volume 17, Issue 1, Pages (January 2009)
Molecular Therapy - Methods & Clinical Development
Development of an HIV-Based cDNA expression cloning system
E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal—Tailored Acceleration of AAV Evolution  Dirk Grimm, Sergei Zolotukhin  Molecular.
Triplex-forming Peptide Nucleic Acids Induce Heritable Elevations in Gamma-globin Expression in Hematopoietic Progenitor Cells  Joanna Y Chin, Faisal.
Volume 24, Issue 1, Pages (January 2016)
Volume 14, Issue 2, Pages (April 2004)
Development of a Novel Recombinant Adeno-Associated Virus Production System Using Human Bocavirus 1 Helper Genes  Zekun Wang, Fang Cheng, John F. Engelhardt,
Molecular Therapy - Methods & Clinical Development
Volume 20, Issue 6, Pages (June 2012)
Molecular Therapy - Methods & Clinical Development
Thomas Gaj, Benjamin E Epstein, David V Schaffer  Molecular Therapy 
Evidence for Encapsidation of Prokaryotic Sequences during Recombinant Adeno- Associated Virus Production and Their in Vivo Persistence after Vector Delivery 
High-level production of replication-defective human immunodeficiency type 1 virus vector particles using helper-dependent adenovirus vectors  Yani Hu,
Volume 24, Issue 4, Pages (July 2018)
DARPins: An Efficient Targeting Domain for Lentiviral Vectors
Biao Dong, Hiroyuki Nakai, Weidong Xiao  Molecular Therapy 
HIV-1 Vif Adaptation to Human APOBEC3H Haplotypes
Volume 22, Issue 11, Pages (November 2014)
Volume 14, Issue 1, Pages (July 2006)
Hildegard Büning, Arun Srivastava 
Molecular Therapy - Methods & Clinical Development
Presentation transcript:

High Capsid–Genome Correlation Facilitates Creation of AAV Libraries for Directed Evolution  Mathieu Nonnenmacher, Harm van Bakel, Roger J Hajjar, Thomas Weber  Molecular Therapy  Volume 23, Issue 4, Pages 675-682 (April 2015) DOI: 10.1038/mt.2015.3 Copyright © 2015 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Low mosaicism in natural adeno-associated virus (AAV) capsid formation. (a) Recombinant viruses were produced with the indicated ratios of Rep-Cap plasmids encoding either wild-type AAV2 or R585/588A mutant (HBDm) capsid, together with an inverted terminal repeat (ITR)-Luciferase-ITR plasmid. Transduction was measured by a luciferase assay. (b) Natural AAV was produced with the indicated ratios of wild-type and HBDm ITR-Rep-Cap-ITR plasmids. Transduction was measured by a DNA replication assay. (c) Recombinant or natural AAV was produced with plasmids encoding a HBD 30-aa insertion mutant (HBDi), wild-type AAV2, or with a 1:1 ratio of these plasmids. Progeny virus was incubated with heparin beads and total or heparin-bound capsids were analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis. (d) Recombinant or natural AAV2 and AAV9 virions were produced alone or in a 1:1 ratio and immunoprecipitated with the AAV2-specific antibody A20. Viral DNA was extracted from the beads or the supernatant and quantified by quantitative polymerase chain reaction (qPCR) with rep primers. (e) Recombinant or natural AAV2 and AAV9 virions were produced alone or in a 1:1 ratio and bound to heparin beads. Viral DNA extracted from the beads or the supernatant was quantified by qPCR with rep primers. Molecular Therapy 2015 23, 675-682DOI: (10.1038/mt.2015.3) Copyright © 2015 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 High capsid–genome correlation in cells transfected with multiple natural adeno-associated virus (AAV)-genome–encoding plasmids. (a) Genotyping of A20 beads and supernatant fractions described in Figure 1d using primers specific for AAV2 or AAV9. (b) Genotyping of heparin beads and supernatant fractions described in Figure 1e using primers specific for AAV2 or AAV9. (c) Inverted terminal repeat–flanked wild-type and HBDm AAV2 DNA were cotransfected in 293T cells at 1:0 to 1:1,000 ratio. Progeny virions were genotyped (left panel) and an equal amount of virus was added to HeLa cells. Cell-bound virions were analyzed by quantitative polymerase chain reaction with primers specific for wild-type or HBDm AAV2. Absolute genomes copies (middle panel) or percentage of total (right panel) are shown. Molecular Therapy 2015 23, 675-682DOI: (10.1038/mt.2015.3) Copyright © 2015 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Adeno-associated virus (AAV) library generation and diversity. (a) Amino acid sequence alignment of hypervariable loop 4 from common human and non-human primate AAV serotypes. The semi-degenerate amino acid sequence used to synthesize the loop IV library is indicated on bottom. (b) Localization of hypervariable loop IV 13-mer on the AAV9 capsid surface. Amino acids submitted to saturating mutagenesis are depicted in red, semiconserved and conserved positions are shown in yellow. The model was generated with MacPymol version 0.99, Schrödinger LLC, http://www.pymol.org (from the file 3ux1_full.vdb downloaded from the Viper database http://viperdb.scripps.edu/). (c) Schematic of the insertion of the loop IV library into an AAV9 plasmid backbone. (d) Analysis of loop IV plasmid library by next-generation sequencing. Nucleotides (top panel) and amino acid (bottom panel) logos are depicted. Degenerate consensus sequences are indicated. Sequence logos were created by weblogo (http://weblogo.berkeley.edu/).22 (e) Titration of viral libraries by quantitative polymerase chain reaction. Values indicate the total viral genomes produced by transfection of one 15-cm plate with various amounts of plasmid library DNA. (f) Measurement of library diversity by next-generation sequencing. The total read counts for each library was ~3.106, minimal diversity was calculated using Poisson distribution estimates. Molecular Therapy 2015 23, 675-682DOI: (10.1038/mt.2015.3) Copyright © 2015 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Stop codon bias in adeno-associated virus (AAV) libraries. (a) Color plot indicating the bias in amino acid frequency at each position of the loop IV 13-mer. Numbers indicate the ratio of AA frequency in viral libraries versus parent plasmid library. Semiconserved and conserved positions 6 and 11 were excluded from the analysis. (b) Scatter plot of total amino acid frequency in the parent plasmid library (x-axis) versus viral libraries (y-axis). Stop codons are indicated in red. (c) Total stop codon frequency in parent and viral libraries. (d) Fitness analysis of variants containing stop codons. Frequency of variants containing at least one stop codon is represented as a function of variant read count quantile. Molecular Therapy 2015 23, 675-682DOI: (10.1038/mt.2015.3) Copyright © 2015 The American Society of Gene & Cell Therapy Terms and Conditions